Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Development of a Ready-to-Use Graphical Tool Based on Artificial Neural Network Classification: Application for the Prediction of Late Fecal Incontinence After Prostate Cancer Radiation Therapy.

Carrara M, Massari E, Cicchetti A, Giandini T, Avuzzi B, Palorini F, Stucchi C, Fellin G, Gabriele P, Vavassori V, Degli Esposti C, Cozzarini C, Pignoli E, Fiorino C, Rancati T, Valdagni R.

Int J Radiat Oncol Biol Phys. 2018 Aug 6. pii: S0360-3016(18)33482-5. doi: 10.1016/j.ijrobp.2018.07.2014. [Epub ahead of print]

PMID:
30092335
2.

Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer: New Insights From External Independent Validation.

Cicchetti A, Avuzzi B, Palorini F, Ballarini F, Stucchi C, Fellin G, Gabriele P, Vavassori V, Esposti CD, Cozzarini C, Fiorino C, Rancati T, Valdagni R.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):127-136. doi: 10.1016/j.ijrobp.2018.05.013. Epub 2018 Jun 30.

PMID:
29970313
3.

Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients: Results from a large pooled population.

Cicchetti A, Rancati T, Ebert M, Fiorino C, Palorini F, Kennedy A, Joseph DJ, Denham JW, Vavassori V, Fellin G, Avuzzi B, Stucchi C, Valdagni R.

Phys Med. 2016 Dec;32(12):1690-1697. doi: 10.1016/j.ejmp.2016.09.018. Epub 2016 Oct 6.

PMID:
27720692
4.

Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials.

Caffo O, Thompson C, De Santis M, Kragelj B, Hamstra DA, Azria D, Fellin G, Pappagallo GL, Galligioni E, Choudhury A.

Radiother Oncol. 2016 Nov;121(2):193-198. doi: 10.1016/j.radonc.2016.09.006. Epub 2016 Oct 5.

PMID:
27720221
5.

Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.

Fellin G, Mirri MA, Santoro L, Jereczek-Fossa BA, Divan C, Mussari S, Ziglio F, La Face B, Barbera F, Buglione M, Bandera L, Ghedi B, Di Muzio NG, Losa A, Mangili P, Nava L, Chiarlone R, Ciscognetti N, Gastaldi E, Cattani F, Spoto R, Vavassori A, Giglioli FR, Guarneri A, Cerboneschi V, Mignogna M, Paoluzzi M, Ravaglia V, Chiumento C, Clemente S, Fusco V, Santini R, Stefanacci M, Mangiacotti FP, Martini M, Palloni T, Schinaia G, Lazzari G, Silvano G, Magrini S, Ricardi U, Santoni R, Orecchia R.

Br J Radiol. 2016 Sep;89(1065):20150981. doi: 10.1259/bjr.20150981. Epub 2016 Jul 7.

6.

Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study.

Veccia A, Caffo O, Fellin G, Mussari S, Ziglio F, Maines F, Tomio L, Galligioni E.

Radiat Oncol. 2015 Jun 10;10:130. doi: 10.1186/s13014-015-0434-4.

7.

Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding phase 2 study.

Maggio A, Magli A, Rancati T, Fiorino C, Valvo F, Fellin G, Ricardi U, Munoz F, Cosentino D, Cazzaniga LF, Valdagni R, Vavassori V.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):518-24. doi: 10.1016/j.ijrobp.2014.03.018. Epub 2014 May 3.

PMID:
24803033
8.

Recurrent prostate cancer genomic alterations predict response to brachytherapy treatment.

Fontugne J, Lee D, Cantaloni C, Barbieri CE, Caffo O, Hanspeter E, Mazzoleni G, Dalla Palma P, Rubin MA, Fellin G, Mosquera JM, Barbareschi M, Demichelis F.

Cancer Epidemiol Biomarkers Prev. 2014 Apr;23(4):594-600. doi: 10.1158/1055-9965.EPI-13-1180. Epub 2014 Feb 10.

9.

Long term rectal function after high-dose prostatecancer radiotherapy: results from a prospective cohort study.

Fellin G, Rancati T, Fiorino C, Vavassori V, Antognoni P, Baccolini M, Bianchi C, Cagna E, Borca VC, Girelli G, Iacopino B, Maliverni G, Mauro FA, Menegotti L, Monti AF, Romani F, Stasi M, Valdagni R.

Radiother Oncol. 2014 Feb;110(2):272-7. doi: 10.1016/j.radonc.2013.09.028. Epub 2013 Dec 11.

PMID:
24332020
10.

Frequency of brain metastases from prostate cancer: an 18-year single-institution experience.

Caffo O, Veccia A, Fellin G, Mussari S, Russo L, Tomio L, Galligioni E.

J Neurooncol. 2013 Jan;111(2):163-7. doi: 10.1007/s11060-012-0994-1. Epub 2012 Oct 25.

PMID:
23096134
11.

Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature.

Caffo O, Veccia A, Fellin G, Russo L, Mussari S, Galligioni E.

Crit Rev Oncol Hematol. 2013 May;86(2):176-90. doi: 10.1016/j.critrevonc.2012.09.011. Epub 2012 Oct 22. Review.

PMID:
23088957
12.

Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial.

Valdagni R, Vavassori V, Rancati T, Fellin G, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Fiorino C.

Radiother Oncol. 2012 May;103(2):252-5. doi: 10.1016/j.radonc.2012.03.012. Epub 2012 Apr 20.

PMID:
22521747
13.

Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model.

Tomatis S, Rancati T, Fiorino C, Vavassori V, Fellin G, Cagna E, Mauro FA, Girelli G, Monti A, Baccolini M, Naldi G, Bianchi C, Menegotti L, Pasquino M, Stasi M, Valdagni R.

Phys Med Biol. 2012 Mar 7;57(5):1399-412. doi: 10.1088/0031-9155/57/5/1399. Epub 2012 Feb 21.

PMID:
22349550
14.

Late fecal incontinence after high-dose radiotherapy for prostate cancer: better prediction using longitudinal definitions.

Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, Valdagni R.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):38-45. doi: 10.1016/j.ijrobp.2011.06.1953. Epub 2011 Oct 8.

PMID:
21985939
15.

Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning.

Perna L, Cozzarini C, Maggiulli E, Fellin G, Rancati T, Valdagni R, Vavassori V, Villa S, Fiorino C.

Radiat Oncol. 2011 Sep 24;6:123. doi: 10.1186/1748-717X-6-123.

16.

Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer.

Rancati T, Fiorino C, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, Valdagni R.

Radiother Oncol. 2011 Jul;100(1):124-30. doi: 10.1016/j.radonc.2011.06.032. Epub 2011 Jul 7.

PMID:
21741721
17.

Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome.

Valdagni R, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G, Cagna E, Gabriele P, Mauro FA, Baccolini M, Bianchi C, Menegotti L, Monti AF, Stasi M, Giganti MO, Fiorino C.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1957-66. doi: 10.1016/j.ijrobp.2011.03.028. Epub 2011 Jun 2.

PMID:
21640511
18.

Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies.

Caffo O, Fellin G, Graffer U, Mussari S, Tomio L, Galligioni E.

Cancer. 2011 Mar 15;117(6):1190-6. doi: 10.1002/cncr.25667. Epub 2010 Oct 19.

19.
20.

Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study.

Fellin G, Fiorino C, Rancati T, Vavassori V, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Valdagni R.

Radiother Oncol. 2009 Nov;93(2):197-202. doi: 10.1016/j.radonc.2009.09.004. Epub 2009 Oct 12.

PMID:
19828205
21.

To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy.

Valdagni R, Rancati T, Ghilotti M, Cozzarini C, Vavassori V, Fellin G, Fiorino C, Girelli G, Barra S, Zaffaroni N, Pierotti MA, Gariboldi M.

Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1431-40. doi: 10.1016/j.ijrobp.2008.10.021. Epub 2009 Feb 11.

PMID:
19211196
22.

Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT.

Valdagni R, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M, Bianchi C, Cagna E, Greco C, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Vavassori V.

Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1065-73. doi: 10.1016/j.ijrobp.2007.11.037. Epub 2008 Jan 30.

PMID:
18234449
23.

Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study.

Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, Girelli G, Mapelli M, Menegotti L, Nava S, Valdagni R.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1130-7. Epub 2007 Sep 19.

PMID:
17881142
24.

Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.

Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, Bianchi C, Cagna E, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Valdagni R.

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1401-10. Epub 2007 Jan 22.

PMID:
17241754
25.

Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer.

Caffo O, Fellin G, Bolner A, Coccarelli F, Divan C, Frisinghelli M, Mussari S, Ziglio F, Malossini G, Tomio L, Galligioni E.

Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):31-7. Epub 2006 Jun 9.

PMID:
16765529
26.

Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101).

Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, Cozzarini C, Fellin G, Foppiano F, Girelli G, Menegotti L, Piazzolla A, Vavassori V, Valdagni R.

Radiother Oncol. 2004 Oct;73(1):21-32.

PMID:
15465142
27.

Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.

Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, Tomio L, Galligioni E.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1310-6.

PMID:
14630267
28.

Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer.

Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, Piazzolla A, Vavassori V, Valdagni R.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):953-62.

PMID:
14575825
29.

The role of brachytherapy in the management of oropharyngeal carcinomas: the Trento experience.

Bolner A, Mussari S, Fellin G, Pani G, Busana L, Caffo O, Tomio L.

Tumori. 2002 Mar-Apr;88(2):137-41.

PMID:
12088254
30.

[Brachytherapy in the management of the initial stage of the mobile tongue carcinoma].

Bolner A, Campolongo F, Segatta P, Fellin G, Bauer M, Nocini PF.

Acta Otorhinolaryngol Ital. 1999 Apr;19(2):80-6. Italian.

PMID:
10434439
31.

A European version of the Appropriateness Evaluation Protocol. Goals and presentation. The BIOMED I Group on Appropriateness of Hospital Use.

Lang T, Liberati A, Tampieri A, Fellin G, Gonsalves Mda L, Lorenzo S, Pearson M, Beech R, Santos-Eggimann B.

Int J Technol Assess Health Care. 1999 Winter;15(1):185-97.

PMID:
10407605
32.

[Intraoperative radiotherapy in the combined treatment of pancreatic cancers].

Fellin G, Pani G, Tomio L, Tirone G, Eccher C.

Tumori. 1999 Jan-Feb;85(1 Suppl 1):S33-5. Review. Italian.

PMID:
10235078
33.

Comparison between two prospective studies of cardiovascular disease carried out amongst renal replacement patients in UK and Italy.

Brown JH, Fellin G, Hunt LP, Vites NP, D'Amico G, Mallick NP.

Nephrol Dial Transplant. 1998 Feb;13(2):449-52.

PMID:
9509461
34.

Hyperfractionated radiation in combination with local hyperthermia in the treatment of advanced squamous cell carcinoma of the head and neck: a phase I-II study.

Amichetti M, Romano M, Busana L, Bolner A, Fellin G, Pani G, Tomio L, Valdagni R.

Radiother Oncol. 1997 Nov;45(2):155-8.

PMID:
9424006
35.

Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.

Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L.

Br J Urol. 1997 Jul;80(1):44-9.

PMID:
9240179
36.

Assessment of quality of life after radical radiotherapy for prostate cancer.

Caffo O, Fellin G, Graffer U, Luciani L.

Br J Urol. 1996 Oct;78(4):557-63.

PMID:
8944512
37.

Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire.

Caffo O, Fellin G, Graffer U, Luciani L.

Cancer. 1996 Sep 1;78(5):1089-97. Erratum in: Cancer 1996 Nov 1;76(9):2037.

PMID:
8780548
38.

[Hyperthermia and palliative radiotherapy for sarcoma].

Amichetti M, Graiff C, Romano M, Bolner A, Busana L, Fellin G, Pani G, Valdagni R.

Radiol Med. 1996 Jun;91(6):796-8. Italian.

PMID:
8830368
39.

[Radiotherapy of T1N0 neoplasms of the glottis. Analysis of the parameters that influence local control].

Bolner A, Valentini A, Amichetti M, Busana L, Fellin G, Menegotti L, Nassivera E, Pani G, Romano M.

Radiol Med. 1995 Dec;90(6):804-7. Italian.

PMID:
8685467
40.

Appropriateness of hospital use: an overview of Italian studies.

Fellin G, Apolone G, Tampieri A, Bevilacqua L, Meregalli G, Minella C, Liberati A.

Int J Qual Health Care. 1995 Sep;7(3):219-25. Review.

PMID:
8595458
41.

Expression of mdm-2 and p53 protein in transitional cell carcinoma.

Barbareschi M, Girlando S, Fellin G, Graffer U, Luciani L, Dalla Palma P.

Urol Res. 1995;22(6):349-52.

PMID:
7537927
42.

Stage I seminoma of the testis: long term results and toxicity with adjuvant radiotherapy.

Amichetti M, Fellin G, Bolner A, Busana L, Pani G, Romano M, Scillieri M, Maluta S.

Tumori. 1994 Apr 30;80(2):141-5.

PMID:
8016907
43.

Critical re-evaluation of 41 cases of "idiopathic" crescentic glomerulonephritis.

Ferrario F, Tadros MT, Napodano P, Sinico RA, Fellin G, D'Amico G.

Clin Nephrol. 1994 Jan;41(1):1-9.

PMID:
8137564
44.

Effect of dietary protein restriction on the progression of renal failure: a prospective randomized trial.

D'Amico G, Gentile MG, Fellin G, Manna G, Cofano F.

Nephrol Dial Transplant. 1994;9(11):1590-4.

PMID:
7870348
45.

Treatment of proteinuric patients with a vegetarian soy diet and fish oil.

Gentile MG, Fellin G, Cofano F, Delle Fave A, Manna G, Ciceri R, Petrini C, Lavarda F, Pozzi F, D'Amico G.

Clin Nephrol. 1993 Dec;40(6):315-20.

PMID:
8299238
46.

Cisplatin, hyperthermia, and radiation (trimodal therapy) in patients with locally advanced head and neck tumors: a phase I-II study.

Amichetti M, Graiff C, Fellin G, Pani G, Bolner A, Maluta S, Valdagni R.

Int J Radiat Oncol Biol Phys. 1993 Aug 1;26(5):801-7.

PMID:
8344849
47.

Typical and atypical natural history of IgA nephropathy in adult patients.

D'Amico G, Ragni A, Gandini E, Fellin G.

Contrib Nephrol. 1993;104:6-13. Review. No abstract available.

PMID:
8325035
48.

Rapidly progressive glomerulonephritis (RPGN): is there still an "idiopathic" subgroup?

Ferrario F, Tadros M, Napodano P, Giordano A, Sinico RA, Fellin G, D'Amico G.

Adv Exp Med Biol. 1993;336:431-4.

PMID:
8296650
49.

Small cell carcinoma of the urinary bladder. Report of two cases and review of the literature.

Amichetti M, Boi S, Fellin G, Maluta S, Dalla Palma P, Luciani L.

Tumori. 1992 Dec 31;78(6):409-13. Review.

PMID:
1338404
50.

Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome.

D'Amico G, Gentile MG, Manna G, Fellin G, Ciceri R, Cofano F, Petrini C, Lavarda F, Perolini S, Porrini M.

Lancet. 1992 May 9;339(8802):1131-4.

PMID:
1349366

Supplemental Content

Loading ...
Support Center